BridgeBio Data to Highlight Long-Term Acoramidis Benefit in ATTR-CM

Event summary

  • BridgeBio will present long-term efficacy and safety data for acoramidis (ATTRibute-CM) at the ACC Annual Scientific Sessions on March 30, 2026.
  • The oral presentation will focus on survival benefits and disease stabilization in patients with ATTR-CM.
  • Three additional posters will detail data on serum transthyretin concentrations, KCCQ-OS scores, and the association between sTTR increase and health status.
  • ATTRibute™ (acoramidis) is indicated for the treatment of ATTR-CM in adults to reduce cardiovascular death and hospitalization.

The big picture

BridgeBio's ATTRibute-CM represents a significant opportunity in the emerging ATTR-CM treatment market, which is driven by increasing awareness and diagnostic capabilities. The long-term data release is a key milestone for the company, as it seeks to establish a durable competitive advantage and expand its commercial footprint. Success hinges on demonstrating sustained efficacy and a manageable safety profile, particularly given the relatively high cost of the therapy.

What we're watching

Clinical Validation
The long-term data presented at ACC will be critical in solidifying the clinical benefit of acoramidis beyond the initial Phase 3 trial, influencing physician adoption and payer coverage decisions.
Competitive Landscape
The presentation's findings will be scrutinized by competitors developing alternative ATTR-CM therapies, potentially impacting BridgeBio's market share and pricing power.
Adverse Event Profile
Continued monitoring of adverse events, particularly diarrhea and upper abdominal pain, will be essential to assess the long-term safety and tolerability of acoramidis in a broader patient population.